サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675295

後天性希少血液疾患治療薬市場：治療薬別、適応疾患別、流通チャネル別、地域別、2025-2033年

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 137 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
後天性希少血液疾患治療薬市場：治療薬別、適応疾患別、流通チャネル別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

後天性希少血液疾患治療薬市場の世界市場規模は2024年に95億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに181億米ドルに達し、2025～2033年の成長率（CAGR）は7.13％になると予測しています。希少血液疾患の診断率の上昇、遺伝子治療や生物製剤の進歩、希少疾病用医薬品の指定や規制上の優遇措置による政府支援の拡大、これらの疾患に対する意識の高まり、治療効果の向上などが、市場成長を後押しする主な要因の一部です。

後天性希少血液疾患は、赤血球（RBC）の産生不能または血液中の赤血球の不足によって引き起こされる稀な血液疾患です。骨髄異形成症候群（MDS）、特発性血小板減少性紫斑病（ITP）、発作性夜間ヘモグロビン尿症（PNH）、骨髄線維症（MF）、真性多血症（PV）、後天性無顆粒球症など、数多くの疾患が含まれます。これらは骨髄の不適切な機能を引き起こし、血小板の数を減少させます。これらの疾患は、遺伝子組換え因子製剤、免疫グロブリン注入療法、活性化プロトロンビン複合体濃縮製剤、トロンボポエチン受容体作動薬など、いくつかの治療法によって治療できるため、後天性希少血液疾患治療薬の需要は世界中で高まっています。

後天性希少血液疾患治療薬市場動向：

現在、血液疾患とその治療法に関する大衆の意識の高まりは、世界の所得水準の上昇とともに、市場にプラスの影響を与える主な要因の1つとなっています。さらに、老年人口の増加による血液疾患治療薬の選択肢に対する需要の高まりが、市場の成長を強化しています。これに伴い、様々な国の政府機関や民間団体が、血液関連疾患の発生に関する認識を個人に広めることで血液疾患治療薬の採用を奨励しており、世界中で様々なヘルスケアイニシアチブを提供していることが、市場の成長を後押ししています。これとは別に、世界中の個人の間で様々な血液関連疾患の有病率が増加しているため、血液疾患治療薬の採用が増加しており、市場の見通しが明るくなっています。さらに、世界中のオンラインおよびオフラインの薬局店を通じて後天性希少疾病の血液疾患治療薬が広く入手可能であることも、市場の成長に寄与しています。これに加えて、世界のヘルスケアインフラの改善とともに、個人の間で個別化された医薬品に対する需要が高まっていることも、業界の投資家に有利な成長機会を提供しています。これに加えて、世界中の個人の間で費用対効果が高く質の高いケアソリューションに対する需要が高まっています。このことは、個人の間で蔓延する疾病を回避するための予防ケアやウェルネス・サービスの採用が増加していることと相まって、市場の成長を後押ししています。さらに、主要メーカーは鎌状赤血球貧血の小児患者向けにヒドロキシ尿素ベースの治療を導入しており、これが市場の成長を支えています。

本レポートで扱う主な質問

  • 世界の後天性希少血液疾患治療薬市場はこれまでどのように推移してきたか？
  • 世界の後天性希少血液疾患治療薬市場における促進要因、抑制要因、機会は何か？
  • 各促進要因、抑制要因、機会が世界の後天性希少血液疾患治療薬市場に与える影響は？
  • 主要な地域市場とは？
  • 最も魅力的な後天性希少血液疾患治療薬市場はどの国か？
  • 治療薬に基づく市場内訳は？
  • 後天性希少血液疾患治療薬市場で最も魅力的な治療薬はどれですか？
  • 適応疾患別の市場内訳は？
  • 後天性希少血液疾患治療薬市場で最も魅力的な適応疾患は？
  • 流通チャネル別の市場内訳は？
  • 後天性希少血液疾患治療薬市場において最も魅力的な流通チャネルは？
  • 市場の競合構造は？
  • 世界の後天性希少血液疾患治療薬市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の後天性希少血液疾患治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療薬別

  • 組み換え因子
  • 免疫グロブリン輸液療法
  • 活性化プロトロンビン複合体濃縮物
  • トロンボポエチン受容体作動薬
  • その他

第7章 市場内訳：適応疾患別

  • 後天性無顆粒球症
  • 後天性血友病
  • 後天性フォン・ヴィレブランド症候群
  • 発作性夜間血色素尿症（PNH）
  • 骨髄異形成症候群
  • その他

第8章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alexion Pharmaceuticals Inc.（AstraZeneca plc）
    • Amgen Inc.
    • GSK plc
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co. Ltd.
    • Rigel Pharmaceuticals Inc.
    • Roche Holding AG
    • Sanofi
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2024
  • Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2024
  • Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
  • Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million USD), 2025-2033
  • Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure
目次
Product Code: SR112025A8217

The global acquired orphan blood diseases therapeutics market size reached USD 9.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.1 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The increasing diagnosis rates of rare blood disorders, advancements in gene therapy and biologics, growing government support through orphan drug designations and regulatory incentives, the rising awareness of these conditions, and improvements in treatment efficacy are some of the major factors propelling the market growth.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

Therapy Insights:

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

Disease Indication Insights:

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the disease indication?
  • Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Recombinant Factor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunoglobulin Infusion Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Activated Prothrombin Complex Concentrate
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Thrombopoietin Receptor Agonists
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

  • 7.1 Acquired Agranulocytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Acquired Hemophilia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Acquired Von Willebrand Syndrome
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Myelodysplastic Syndrome
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Novo Nordisk A/S
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Otsuka Pharmaceutical Co. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Rigel Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Roche Holding AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Sanofi
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.